Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 2/20 | 0.51 |
| ▸ | NT5E | P21589 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.38 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.38 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909164 | 0.87 | HTR5A (0.49) | HTR5ANT5ESMN1; SMN2TDP1 | |
| SCHEMBL9909235 | 0.86 | NT5E (0.47) | HTR5ANT5ESMN1; SMN2NR4A2CSNK2A1 | |
| SCHEMBL9909302 | 0.85 | HTR5A (0.73) | HTR5ANT5E | |
| SCHEMBL9907333 | 0.82 | HTR5A (0.72) | HTR5ASMN1; SMN2IP6K1IP6K3IP6K2 | |
| SCHEMBL9109054 | 0.80 | GRM2 (0.60) | HTR5AGRM2 | |
| SCHEMBL12875049 | 0.79 | HTR5A (0.56) | HTR5ANT5EGRM2 | |
| SCHEMBL9907513 | 0.79 | HTR5A (0.50) | HTR5ASMN1; SMN2IP6K1IP6K3IP6K2 | |
| SCHEMBL9907541 | 0.79 | HTR5A (0.53) | HTR5ASMN1; SMN2NR4A2CSNK2A1GRM2 | |
| SCHEMBL9909166 | 0.79 | HTR5A (0.50) | HTR5ANR4A2CSNK2A1GRM2TDP1 | |
| SCHEMBL9108194 | 0.77 | HTR5A (0.48) | HTR5AIP6K1IP6K3IP6K2NR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2011016504-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885NT5E 266/4885SMN1; SMN2 3684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.